There were no cases of ALT increase during prelicensure study [28], whereas phase II/III trials reported a mild rate (4.5–20%) of ALT elevations (G3/4: 1–1.9%) in monotherapy, which significantly increased when the drug was used in combination with Obinutuzumab (30% and 7%, respectively), however without cases of liver failure [29,30,31,32,33,34]. Here, GPT is linked to Hepatic failure.